Bladder cancer patients have increased NETosis and impaired DNaseI-mediated NET degradation that can be therapeutically restored < em > in vitro < /em >

CONCLUSION: To the best of our knowledge, this is the first report demonstrating that BC patients have an increased NETosis systemically and in the tumor microenvironment, in part caused by an impaired DNaseI-mediated NET degradation. Remarkably, this defect can be therapeutically restored in vitro with the approved Dornase alfa, thus Pulmozyme® could become a potential therapeutic tool to locally reduce BC progression.PMID:37275882 | PMC:PMC10237292 | DOI:10.3389/fimmu.2023.1171065

Source: Cancer Control - June 5, 2023 Category: Cancer & Oncology Authors: Raquel Herranz Julia Oto Marta Hueso Emma Plana Fernando Cana Mar ía Castaño Lourdes Cord ón David Ramos-Soler Santiago Bonanad C ésar D Vera-Donoso Manuel Mart ínez-Sarmiento Pilar Medina Source Type: research